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Background: Antipsychotic drugs are widely used for the treatment of Behavioral and Psychological Symptoms of
Dementia (BPSD), despite their limited efficacy and concerns about safety. The aim of this study was to describe
antipsychotic drug therapy among people with dementia living in specialized care units in northern Sweden.
Methods: This study was conducted in 40 specialized care units in northern Sweden, with a total study population
of 344 people with dementia. The study population was described in regard to antipsychotic drug use, ADL
function, cognitive function and BPSD, using the Multi-Dimensional Dementia Assessment Scale (MDDAS). These
data were collected at baseline and six months later. Detailed data about antipsychotic prescribing were collected
from prescription records.
Results: This study showed that 132 persons (38%) in the study population used antipsychotic drugs at the start of
the study. Of these, 52/132 (39%) had prescriptions that followed national guidelines with regard to dose and
substance.
After six months, there were 111 of 132 persons left because of deaths and dropouts. Of these 111 people, 80
(72%) were still being treated with antipsychotics, 63/111 (57%) with the same dose. People who exhibited
aggressive behavior (OR: 1.980, CI: 1.515-2.588), or passiveness (OR: 1.548, CI: 1.150-2.083), or had mild cognitive
impairment (OR: 2.284 CI: 1.046-4.988), were at increased risk of being prescribed antipsychotics.
Conclusion: The prevalence of antipsychotic drug use among people with dementia living in specialized care units
was high and inappropriate long-term use of antipsychotic drugs was common.
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Dementia is a disorder that causes permanent and pro-
gressive impairment of cognitive functions such as mem-
ory and other cognitive abilities [1]. Behavioral and
Psychological Symptoms of Dementia (BPSD) is the term
applied to the various problems that complicate demen-
tia and prevalence is high. It is estimated that up to 90%
of patients with Alzheimer’s disease may present at least
one BPSD during the course of the disease [2]. BPSD
include behaviors such as aggression, screaming, rest-* Correspondence: maria.gustafsson@pharm.umu.se
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distribution, and reproduction in any mediumlessness, and also symptoms such as anxiety, hallucina-
tions and depressive mood [3].
Antipsychotic drugs are widely used for the treatment
of certain BPSDs; one study showed that 40% of elderly
people with cognitive impairment living in group dwell-
ings took antipsychotic drugs [4]. However, antipsychotic
drugs have demonstrated only limited efficacy in the
treatment of BPSD. A systematic review found that first
generation antipsychotics had little efficacy at best, and
that the benefits may not outweigh the risk of side
effects [5]. The same review showed that olanzapine and
risperidone had a modest, statistically significant efficacy
with minimal adverse effects at lower doses [5]. How-
ever, in another study, adverse effects offset the clinicaltral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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ment of BPSD [6].
Older people tend to experience side-effects more fre-
quently and with greater severity than younger people,
and antipsychotic drugs have a number of side-effects.
First generation antipsychotics are associated with a high
prevalence of extrapyramidal side-effects (EPS) and tard-
ive dyskinesia due to their high affinity for D2-receptors
[7]. Second generation antipsychotics have a different
receptor-binding profile. Since they interact with both
D2 and 5HT2-receptors, they cause EPS to a lesser ex-
tent [8]. The use of antipsychotic drugs appears to be
associated with accelerated cognitive decline in people
with Alzheimer’s disease; treatment with haloperidol
over 6–8 weeks was associated with a decline in cogni-
tion measured using the Mini-Mental State Examination
(MMSE) [9]. However, one study showed that the
MMSE score did not worsen after treatment with risper-
idone among people with dementia [10], which might be
due to the lack of anticholinergic activity of risperidone
[11]. All antipsychotics seem to cause metabolic side-
effects. However, it appears that second generation
antipsychotics are worse in this regard, even if there is
variation among substances in this group [12].
Second generation antipsychotics have also been asso-
ciated with an increased risk of cerebrovascular events
and increased mortality, and first generation antipsycho-
tics seem to carry the same risk [13,14].
Support for the long-term use of antipsychotics in this
patient population is limited. There is some evidence
favoring short-term use, [1,15] even if it is considered an
option of last resort. Even short-term use of antipsycho-
tics increases the risk of serious adverse events [16].
According to the Swedish Medical Products Agency, the
dose should initially be low and then titrated upwards
and treatment should be time-limited and regularly
reviewed [1]. Only two recent studies have described
long-term antipsychotic treatment among people with
dementia [17,18] and both found relatively high rates of
long-term treatment. There is still a need for detailed
study of the long-term use of antipsychotic in this popu-
lation. The aim of this retrospective study was to de-
scribe the prevalence, associated factors and long-term
use of antipsychotic drugs among people with dementia
living in specialized care units.
Methods
Subjects and settings
The study population for this project has previously
been used in a research study concerning use of physical
restraint [19]. This was an intervention study conducted
in 2005-2006, which included 40 specialized care units
(353 people) in nine communities in northern Sweden.
These units are designed to provide care for six to eightpersons with dementia in homelike environments. All
specialized care units in these communities were inven-
toried, i.e. 99 units were contacted - and units with the
highest prevalence of physical restraint use (≥20%) were
selected. In the present study, 9 people were excluded
due to incomplete data. The study was approved by the
Regional Ethical Review Board in Umeå (registration
number 02-105).
Procedures
Data were collected by means of a questionnaire com-
pleted by care unit staff, the Multi-Dimensional Demen-
tia Assessment Scale (MDDAS) [20]. The MDDAS has
good intra- and inter-rater reliability [20]. This instru-
ment includes assessment of the level of functioning in
activities of daily living (ADL), cognition and behavioral
and psychological symptoms. ADL function score ranges
from 4-24, where a higher score indicates greater ADL
independence. This score is based on the person’s ability
to cope with hygiene, dressing, eating and bladder and
bowel control. Cognitive function was measured using
an assessment scale developed by Gottfries and Gottfries
[21]. This scale ranges from 0-27 points and a score of
less than 24 is considered to indicate cognitive impair-
ment, correlating with a sensitivity of 90% and a specifi-
city of 91% to the usual cut-off point of the MMSE (24/
30) [21,22]. The scale is further subdivided into three
groups - mild cognitive impairment (16-23), moderate
cognitive impairment (8-15) and severe cognitive impair-
ment (0-7). The MDDAS contains 25 behavioral items
and 14 psychological symptom items. Each item is rated
on a three-point scale indicating that the symptom was
present at least once a day, once a week, or never during
the observation period of one week. These variables are
dichotomized between at least once a week and less than
once a week in the present study.
All persons’ prescription records were collected at the
start of the study and six months later. The majority of
people dispensing service where the used an automat-
ed multidose dispensing service where the persons’
drugs are dispensed in one dose unit bag for each dose
occasion.
The prescription records were searched to identify
those people from the study population treated with
antipsychotic drugs. All people were listed by age, sex,
and treatment with antidepressants (N06A), anxiolytics,
hypnotics and sedatives (N05B&C), anti-dementia drugs
(N06D), and antipsychotics (N05A). The WHO ATC
(Anatomical Therapeutic Chemical Index) classification
system was used.
Information about dose and type of antipsychotic drugs
was collected, and also indication for treatment when this
was reported in the prescription records. These indica-
tions are written by the prescribing physicians to describe
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scribed the drug. Also, the pharmacy uses the indication
to check the appropriateness of drug choice and dose.
Lithium (N05AN01) was not included since it differs
from antipsychotics regarding both mechanism of action
and use. Pro re nata (PRN) drugs were also not included, as
information was lacking on the actual use of these drugs,
and furthermore very few people used PRN antipsychotics.
To be able to compare antipsychotic doses between
baseline and follow-up, we calculated all antipsychotics
in haloperidol equivalents. Recommendations concern-
ing antipsychotic use vary slightly in different guidelines
[1,15]. Since this study was conducted in Sweden, we
used the guidelines from the Swedish Medical Products
Agency to evaluate the appropriate use of antipsychotics
[1]. These guidelines state that risperidone is the only
antipsychotic drug that is labeled for use in combating
BPSD in Sweden, and the recommended dose is ≤1.5 mg
daily. According to the same guidelines, the indications
that justify the prescribing of antipsychotic drugs in
people with BPSD are psychotic symptoms and aggres-
sive behavior that causes suffering or potential danger
for the person or others.
Statistics and calculations
People who did and did not take antipsychotics were com-
pared using the Pearson chi-square test and t-test for di-
chotomous and continuous variables respectively. SPSS 18
for MacOS X was used for data handling and statistical
calculations. A p-value of < 0.05 was considered statisti-
cally significant. A multiple logistic regression model was
constructed to find factors independently associated with
antipsychotic drug use. The behavioral and the psycho-
logical symptom items of the MDDAS were grouped and
weighted (in each group every symptom was multiplied
with the calculated factor loading and then added with
next symptom) according to a factor analysis previously
described by Lövheim et al [23]. The factors were then
normalized and included in a logistic regression model
which also included age, sex and level of cognitive impair-
ment. As many of the behavioral and psychological symp-
toms correlated strongly, the behaviors and symptoms
were tested in the regression model in a stepwise proced-
ure, where the behavior that had the strongest bivariate
correlation (aggressive behavior) was included first, and all
other behaviors and symptoms were included subse-
quently one by one to see if any of them contributed
independently. These behaviors and factors, apart from
aggressive behavior, were: wandering behavior, restless be-
havior, verbally disruptive/ attention-seeking behavior,
passiveness, hallucinatory symptoms, depressive symp-
toms, disoriented symptoms and regressive/inappropriate
behavior. Ultimately, all significant behaviors and symp-
toms were included in a final model.Survival among people who were treated with anti-
psychotic drugs at the start of the study was compared
with those who were not treated with antipsychotics,
using a Cox regression, also including age, sex and level
of cognitive impairment.
Results
The study population comprised 344 people with de-
mentia whose characteristics are presented in Table 1.
One hundred and thirty-two (38%) of these people used
antipsychotic drugs at the start of the study; 118 people
were prescribed one antipsychotic drug, 13 took two,
and 1 person had three antipsychotic drugs prescribed
concomitantly. Ninety prescriptions were for second
generation antipsychotics, and 57 for first generation
antipsychotics. There were no associations between anti-
psychotic drug use and antidepressant drug use, or be-
tween antipsychotic drug use and anti-dementia drug
use. However, there was an association between anti-
psychotic drug use and anxiolytic, hypnotic and sedative
drug use, as shown in Table 1. An association was found
between antipsychotic drug prescribing and age, but no
difference between men and women.
The multiple logistic regression analysis showed that
those who exhibited an aggressive behavior, or passive-
ness, were younger or had mild cognitive impairment
as compared to severe cognitive impairment, were at
increased risk of being prescribed an antipsychotic
drug (Table 2).
After six months, 111 people remained to be evaluated
of those who were treated with antipsychotics at baseline
(7 dropouts, 14 deceased), as presented in Figure 1. Of
these 111 people, 80 (72%) were still being treated with
antipsychotics, 63 of these with the same dose. Seventy-
eight people of 80 were taking the same antipsychotics
as before. Of those who were not treated with antipsy-
chotics at baseline, 10 people were receiving antipsycho-
tics at the 6- month follow-up. After six months, 31
persons had ended their treatment with antipsychotics.
The mean age of this group was 83.1, compared to 80.0
among those who still were using antipsychotics after six
months (80 persons). However, this difference was not
significant. No significant differences were seen concern-
ing ADL, cognitive score or sex.
The mortality analysis showed no difference in mortal-
ity between those who received antipsychotics at the
start of the study and those who did not (OR 0.69, CI
0.36-1.32, p-value 0.26).
At the start of the study, 132 people were prescribed
antipsychotic drugs; 62 of these received risperidone, the
only antipsychotic drug that is labeled for use in BPSD
in Sweden, as shown in Table 3. Of these 62, 52 received
the recommended dose, i.e. ≤1.5 mg daily. Hence, 52/
132 (39%) received both recommended antipsychotic
Table 1 Characteristics of study population and comparison between people with and without antipsychotics
With AP Without AP Total p-value
Cases, n (%) 132 (38.4) 212 (61.6) 344
Women, n (%) 92 (69.7) 153 (72.2) 245 (71.2) 0.62
Mean age ± SD 80.9 ± 8.6 82.9 ± 7.2 82.1 ± 7.8 0.02
ADL score (4-24) mean ± SD 11.9 ± 5.2 12.2 ± 5.4 12.1 ± 5.3 0.63
Cognitive score (0-27) mean ± SD 10.6 ± 7.4 10.0 ± 7.2 10.2 ± 7.3 0.47
Antidepressant (N06A) use, n (%) 73 (55.3) 107 (50.5) 180 (52.3) 0.38
Anxiolytics, hypnotics and sedatives (N05B&C) use, n (%) 72 (54.5) 84 (39.6) 156 (45.3) 0.007
Anxiolytics (N05B) use, n (%) 28 (21.2) 18 (8.5) 46 (13.4) 0.001
Hypnotics and sedatives (N05C) use, n (%) 63 (47.7) 76 (35.8) 139 (40.4) 0.029
Anti-dementia drugs (N06D) use, n (%) 26 (19.7) 45 (21.2) 71 (20.6) 0.733
SD= Standard Deviation, ADL= activities of daily living, AP= Antipsychotic drug.
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chotics were used solely for the treatment of BPSD.
The indications for prescribing antipsychotic drugs to
this patient group are listed in Table 4. The most com-
mon indication was “treatment of disturbed and restless
behavior/sedative”. No indication was listed for 19 pre-
scriptions. After six months, ten people who did not re-
ceive antipsychotics at baseline, had been started on
antipsychotic drugs. Of these ten, one received risperi-
done and nine people received other antipsychotics. The
dose of risperidone of this one person, however, was
higher than the recommended dose. The most common
indication was “treatment of disturbed and restless be-
havior/sedative”, similar to those having antipsychotics
at study start.
Discussion
This study showed that many people with dementia who
lived in specialized care units were prescribed anti-





Male sex 0.969 0.546-1.719 0.913
Higher age 0.958 0.924-0.993 0.018
Moderate cognitive impairmenta 1.802 0.973-3.338 0.061
Mild cognitive impairmenta 2.284 1.046-4.988 0.038
Aggressive behavior 1.980 1.515-2.588 <0.001
Passiveness 1.548 1.150-2.083 0.004
Model Cox and Snell R2: 0.129, concordance between observed and predicted
value: 67.6%. a Cognitive score ranges from 0-27 points and a score of less
than 24 is considered to indicate cognitive impairment. The scale is
subdivided into three groups, 0-7 (severe cognitive impairment), 8-15
(moderate cognitive impairment) and 16-23 (mild cognitive impairment).
Severe cognitive impairment is reference category.cases the doses were probably not regularly adjusted; a
majority of the people appeared to be on stable doses for
six months or possibly longer. There were also few
people in our study who had been prescribed the drugs
in agreement with current recommendations concerning
dosage and drug choice. The study showed that people
who exhibited aggressive behavior, or passiveness, or had
a higher cognitive score, were at increased risk of being
prescribed antipsychotics. Those who received antipsycho-
tics were also significantly younger. We found no differ-
ence between men and women concerning antipsychotic
drug use.
Furthermore, the use of more than one psychotropic
drug seemed to be common, 72/344 had anxiolytics/
hypnotics/sedatives and an antipsychotic drug pre-
scribed simultaneously and 73/344 had antidepressants
and an antipsychotic drug prescribed simultaneously. In
addition, 14 persons had more than one antipsychotic
drug prescribed.
The present results are in accordance with previous
studies. One study found that people received psycho-
tropic drugs over at least one year despite uncertainty
about symptom improvement and another study showed
that most antipsychotic prescriptions remained un-
changed over a six-month period [17,18]. In the present
study, 63/111 (57%) received exactly the same anti-
psychotic dose after six months. The high prevalence of
long-term use is not in line with current recommenda-
tions which emphasize that treatment should be time-
limited and regularly reviewed [15]. Selbæk et al also
demonstrated that most symptoms show an intermittent
course which does not support long-term treatment with
antipsychotics [18]. O’Connor et al discuss the fact that
the person’s symptoms are classified as present when in
reality they occur only occasionally [17]. These findings
stress the importance of reviewing antipsychotic use
regularly to ensure that the indication remains. One











After 6 months 
173 left 
After 6 months 
7 dropouts 








6 higher dose 
11 lower dose 
63 same dose 
10 with  
antipsychotics
163 without  
antipsychotics
Figure 1 Flow chart of participants from baseline to 6-month follow-up.
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ation antipsychotics, and another study found that
people actually improved when second generation anti-
psychotics were withdrawn [25,26].
Furthermore, the indications that were given for the
prescriptions in our study were not in line with the
recommendations. By far the most common indication
in this study was “treatment of disturbed and restless
behavior/sedative”, and this is not an approved indica-
tion, according to the guidelines. Some indications were
doubtful and in many cases were missing. However,
these results should be interpreted with caution since
the indications often overlap and the way of expressionTable 3 Characteristics of antipsychotic drugs at the start of t







Haloperidol 25 17.0 2.1±3.1 1.0
Levomepromazine 12 8.1 19.6±15.6 15.0
Zuclopenthixol 6 4.1 3.7±2.0 3.0
Dixyrazine 5 3.4 32.0±38.3 20.0
Melperone 4 2.7 33.8±11.1 30.0
Perphenazine 4 2.7 7.8±5.9 6.0
Chlorpromazine 1 0.7 100.0
Second generation AP
Risperidone 62 42.2 1.1±1.1 0.8
Olanzapine 18 12.2 6.9±5.1 5.0
Ziprasidone 6 4.1 60.0±31.0 50.0
Clozapine 3 2.0 216.7±332.0 25.0
Quetiapine 1 0.7 50.0
Number of prescriptions=147, number of persons taking AP=132, AP=antipsychoticmight differ between physicians. The choice of anti-
psychotic drugs among prescribers in this study was
somewhat surprising considering that the second gener-
ation antipsychotics risperidone and olanzapine seem to
have the best evidence-base for effectiveness, compared
to placebo for physical aggression, agitation and psych-
osis [27,28]. Risperidone and haloperidol were the most
commonly used antipsychotics in our study, which is to
be expected. Haloperidol has little anticholinergic activ-
ity and was by many considered the most preferable
antipsychotic to people with dementia before the in-
troduction of the second generation antipsychotics. An
established treatment tradition might possibly havehe study
Range (mg) Mean Dose (mg)
Haloperidol equivalents
Halo-peridol














Table 4 Indications for antipsychotic treatment at the
start of the study
Treatment of disturbed and restless behavior/sedative n (%) 67 (42.9)
Delusions/hallucinations/paranoia n (%) 16 (10.3)
Treatment of mood/irritability/anxiety, n (%) 14 (9.0)
Treatment of aggression, n (%) 13 (8.3)
Treatment of insomnia, n (%) 12 (7.7)
Treatment of psychosis, n (%) 7 (4.5)
Treatment of confusion, n (%) 3 (1.9)
To combat behavioral disorders/BPSD, n (%) 2 (1.3)
Other indications, n (%) 3 (1.9)
No indication, n (%) 19 (12.2)
Indication at baseline. Number of prescriptions=147, number of persons taking
antipsychotics=132. The number of indications (156) is higher since there were
sometimes more than one indication per prescription.
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plain why many old people with dementia were still trea-
ted with haloperidol in 2006. Haloperidol has some
efficacy against behavioral problems in higher doses, but
its use is limited by side-effects [1]. Risperidone on the
other hand is a well-tolerated alternative among people
with dementia in lower doses [29] and is, as stated
above, the only antipsychotic drug that is labeled for use
in BPSD in Sweden. The proportion of people with anti-
psychotics treated with second generation drugs will
probably continue to increase [30].
A more unexpected finding was the fact that these two
drugs did not account for a larger share of the anti-
psychotic prescriptions. Many older first generation anti-
psychotics and also some of the newest second generation
antipsychotics were used to treat BPSD in this patient
group. The reason prescribing physicians deviated from
current guidelines is unclear. This study was conducted in
2005 and 2006, i.e. 2-3 years before the guideline was
issued. Possibly, the prescription may have changed due to
new recommendations, however, we still find it relevant to
compare the treatment with what is now considered to be
appropriate medication.
However, there are other possibilities for treating BPSD
in persons with dementia. Primarily, non-pharmacological
approaches are recommended, such as investigation /sur-
vey of symptoms, possible causes and triggering moments.
It is also important to review current pharmacological
treatment and consider discontinuation of drugs with po-
tentially adverse effects on the central nervous system and
finally, to optimize the care environment and treatment
[1,31]. For example, it has been shown that music, phys-
ical exercise and recreation might have some effect con-
sidering psychological symptoms in people with dementia
[32]. When it comes to pharmacological treatment, mem-
antine, cholinesterase inhibitors and SSRI have shown
positive efficacy in various studies [33-39]. Among anti-dementia drugs, memantine appears to reduce specific
problems such as agitation and irritability [34]. Concern-
ing cholinesterase inhibitors, one meta-analysis showed
that rivastigmine had positive effects on nonpsychotic and
psychotic symptoms associated with Alzheimer’s disease
[35]. Among antidepressants, citalopram has for example
showed significant efficacy against behavioral disturbances
in individuals with dementia [36,37], and sertraline has
showed efficacy against aggressive behavior [38]. Selective
serotonin reuptake inhibitors are also recommended as
first line treatment for irritability, agitation and anxiety
among people with dementia [1].
The association found between antipsychotics and ag-
gressive behavior, as well as the association between
antipsychotic use and lower age, confirms the results of
an earlier study [4]. The increased risk of receiving
antipsychotic treatment among people with aggressive
behavior might be expected since this is one of the
approved indications for antipsychotics. We also found
an association between use of antipsychotics and a
higher cognitive score. It has been shown that the
prevalence of the behaviors and symptoms decline in
those with severe cognitive impairment, and this might
possibly lead to less use of antipsychotics [23]. There
was also an association between passiveness and use of
antipsychotics in the present study. It has been shown
that passiveness increases almost linearly with the se-
verity of cognitive impairment [23]. It can be difficult
to know what is cause and what is effect, but the pas-
siveness shown among those who use antipsychotic
drugs might also, in some cases, be a side-effect of the
antipsychotics.
This study did not show any difference in mortality
between those who received antipsychotics at the start
of the study and those who did not. Several studies have
reported an increased mortality among people pre-
scribed antipsychotics, [13,14] while other studies have
not - for example one study that found no association
between antipsychotics and cerebrovascular events com-
pared to benzodiazepines [40]. A selection effect, where
the healthier persons were possibly prescribed antipsy-
chotics more frequently, might have contributed to our
results considering mortality and antipsychotics. We did
not know the length of exposure to antipsychotics, only
that a person was treated with an antipsychotic drug at
the start of the study and this have possibly influenced
the results. Also, in this study we lacked information
about the prevalence of cerebrovascular diseases and
other co-morbidities that might have impacted on
mortality.
In this study we have been able to describe in detail
long-term use of antipsychotics among people with de-
mentia. The registration of drugs and doses in the
present study was of high quality. We can also assume
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patients used an automated dose dispensing system.
The study also has some methodological limitations.
The selection of specialized care units was not random
but based on the prevalence of physical restraint use. It
could be that people in these homes have severe pro-
blems with BPSD and, therefore, receive long-term treat-
ment to a greater extent. In the physical restraint study
[19] there was no difference in antipsychotic use within
groups or between groups at baseline and after six
months, but we have not been able to compare data with
non-selected units since we do not have that informa-
tion. However, the proportion of those who were on
antipsychotic drugs does not appear to differ from those
found in other studies [4]. We believe that this does not
affect the main results of the study, but it should be
borne in mind when interpreting the results.
Data were registered at the start of the study and six
months later, but what happened between those times is
not known, except for mortality. We do not know the
duration of antipsychotic treatment at the time of re-
cruitment into the study, and we also do not know if
any attempts of dose reduction or attempts of non-
pharmacological treatment of BPSD have been made.
Further, we do not know the background or other dis-
eases of the participants, and we lack information about
adverse effects of antipsychotics e.g. extrapyramidal
effects or falls.
In our study, there could possibly have been reasons
other than BPSD for prescribing antipsychotics. Some
people might have schizophrenia or other chronic psych-
otic illnesses where recommendations about dose and
substance differ from recommendations among people
with dementia. This might, to some extent, explain the
use of other antipsychotic drugs or higher doses.
Still, the reason for prescribing antipsychotics is prob-
ably related to BPSD in the vast majority of cases,
among old people with dementia living in specialized
care units.
Conclusion
The prevalence of antipsychotic drug use among people
with dementia living in specialized care units was high
and inappropriate long-term use of antipsychotic drugs
was common. The prescriptions were often not in agree-
ment with current recommendations.
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